NKTX
Nkarta Inc.
$2.25
$0.00(0.00%)
50
Overall
60
Value
40
Tech
--
Quality
Market Cap
$139.21M
Volume
484.87K
52W Range
$1.42 - $2.81
Target Price
$11.60
Company Overview
| Mkt Cap | $139.21M | Price | $2.25 |
| Volume | 484.87K | Change | +0.00% |
| P/E Ratio | -1.3 | Open | $2.33 |
| Revenue | -- | Prev Close | $2.25 |
| Net Income | $-108.8M | 52W Range | $1.42 - $2.81 |
| Div Yield | N/A | Target | $11.60 |
| Overall | 50 | Value | 60 |
| Quality | -- | Technical | 40 |
No chart data available
About Nkarta Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Sector: Industrials
Industry: Pharmaceutical Preparation Manufacturing
Latest News
Analysts Are Bullish on Top Healthcare Stocks: Nkarta (NKTX), BioCardia (BCDA)
Howard Kim•12 days ago
Nkarta Launches $100 Million At-the-Market Stock Offering
TipRanks Auto-Generated Newsdesk•13 days ago
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NKTX | $2.25 | 0% | 484.87K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |